GlassScriptPhysician profile
Adonis S Al Botros
NPI 1316994551
$72,714.07
in general payments reported to CMS, 2019-2025
36 companies · $3,217 in 2025
The $3,217 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $9,873 · 2021: $13K · 2022: $16K · 2023: $12K · 2024: $6,744 · 2025: $3,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $9,898 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,880.00 |
| Food and Beverage | $9,898.15 |
| Education | $211.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25,833.58 | 2020-2025 | Caplyta |
| Abbvie INC. | $10,251.77 | 2021-2025 | Vraylar, Ubrelvy |
| Allergan, INC. | $8,443.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $6,418.10 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $4,605.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $3,023.11 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Indivior INC. | $2,217.99 | 2019-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $1,736.35 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,706.80 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,529.97 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,149.11 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $808.41 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $702.53 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $667.77 | 2021-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $589.96 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $438.77 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $433.00 | 2019-2024 | Jornay Pm |
| Corium, LLC | $360.06 | 2022-2023 | Azstarys |
| Tris Pharma INC | $236.03 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $214.48 | 2022-2025 | Loreev Xr |
| Shire North American Group INC | $166.24 | 2019 | |
| Noven Therapeutics, LLC | $161.98 | 2023-2025 | Secuado, Xelstrym |
| Vertical Pharmaceuticals, LLC | $149.30 | 2019-2020 | |
| Eisai INC. | $133.83 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $133.24 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $113.63 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $98.58 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $97.86 | 2019 | |
| Neos Therapeutics, LP | $66.52 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $60.14 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $47.98 | 2019-2021 | |
| Adlon Therapeutics L.P. | $34.18 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $32.98 | 2019 | |
| Noven Pharmaceuticals, INC. | $23.55 | 2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $13.53 | 2019 | |
| Livanova USA, INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adonis Al Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.